Abnormally high expression of programmed death-ligand 1 (PD-L1) on tumor cells and antigen-presenting cells in the tumor microenvironment mediates tumor immune escape, since PD-L1 binding to its receptor, programmed death-1 (PD1) on the surface of T

The claudin 18.2 IHC kit is intended to detect claudin 18.2 protein in formalin-fixed, paraffin-embedded (FFPE) tissue sections in vitro by IHC and to assist in the identification of malignant tumor patients who benefit from the treatment with target

Mismatch Repair (MMR) occurs in the process of DNA replication, recombination and damage repair, and can recognize and repair erroneous insertions, deletions and integrations. Four common mismatch repair proteins in the human body, namely hMLH1, hMSH

This kit uses PCR+CE methods to detect nine mononucleotide repeat sites including BAT25, BAT26, NR21, NR24, MONO27, BAT52, BAT56, BAT59, and BAT60 in tumor tissues to guide the diagnosis of colorectal cancer patients, especially treated with immune c

The c-MET exon 14 skipping mutation exists in a variety of solid tumors, mainly in non-small cell lung cancer (NSCLC). The mutation rate in lung adenocarcinoma is about 3%, and the mutation rate in lung squamous cell carcinoma is about 2%, especially

c-MET is a proto-oncogene that encodes a transmembrane receptor for Hepatocyte Growth Factor (HGF) and has Tyrosine Kinase (TKs) activity. Abnormal c-MET is related to the occurrence and development of various tumors. The detection of abnormal c-MET

The transmembrane receptor-like protein encoded by the proto-oncogene Human Epidermal Growth Factor Receptor 2 (HER2) gene has tyrosine kinase activity, and HER2 is an important prognostic factor for breast cancer. Breast cancer with HER2 gene amplif

Prostate cancer is one of the most common malignant tumors of the urinary system. Androgen receptor (AR) plays an important role in the occurrence and development of prostate cancer. It promotes the progression and metastasis of prostate cancer by re

The Pan-Solid Tumor 95- Gene Panel Assay is a small panel product for solid tumors independently developed by MEDx Translational Medicine. It covers relevant genes with clear drug significance recommended by authoritative guidelines. Probe-Based Hybr

HEMECDx, a high-throughput gene assay developed by MEDx Translational Medicine (Suzhou) Co., Ltd, is used to detect abnormal mutations of key genes in hematological malignancies like leukemia and lymphoma. MEDx provides physicians and patients with s

B cell receptor (BCR) sequencing panel is used to detect the rearrangement of human B lymphocyte receptor gene in relative quantitation. The results of this assay mainly assist the diagnosis of ALL, MM and CLL by detecting BCR gene rearrangement, so

This assay has been developed with selected 601 tumor-related genes that cover all the genes of both FDA-approved FoundationOne panel and MSK-IMPACT panel. It can detect the mutation and fusion of the genes to predict the response to a targeted thera

OncoCDx Panel is a pan-solid tumor panel product independently developed by MEDx Translational Medicine. This assay uses Probe-Based Hybridization Capture and Next Generation Sequencing (NGS) technology for the detection of gene mutations, such as po

HRDetectCDx Panel is an HRD score detection Panel independently developed by MEDx Translational Medicine. It is based on 41,000+ high-quality single nucleotide polymorphism sites (SNPs) screened by ChinaMap database of 10,000 individuals. By analyzin

Fibroblast Growth Factor Receptor (FGFR) pathway plays an important role in the occurrence and development of many tumors. The panFGFx was independently developed by MEDx Translational Medicine to detect genes of FGFRs, the upstream FGFs ligand genes

HEMECDx is a high-throughput gene detection product for leukemia and lymphoma patients independently developed by MEDx Translational Medicine (Suzhou) Co., Ltd. (MEDx). MEDx provides physicians and patients with a number of products used to conduct a

The c-MET gene encodes a tyrosine kinase-type receptor, and its ligand is hepatocyte growth factor (HGF). c-MET is the only known HGF high-affinity receptor. HGF activates c-MET after binding to c-MET, which causes cell proliferation, migration, diff

MPN is a group of clonal hematopoietic stem cell diseases characterized by the continuous proliferation of one or more myeloid lineages in the bone marrow. The WHO 2016 classification of MPN includes seven sub-types, among which PV, ET and PMF are co